Established in 2022, privately-owned Relief Cardiovascular’s mission is to reduce the burden associated with congestive heart failure.  The Company is focused on the development of transcatheter smart implant systems to enhance volume management in heart failure.  Its first-generation Relief System for inferior vena cava flow modulation is entering OUS clinical investigation in late 2025.

Diuretics remain a cornerstone for volume management in heart failure. However, diuretic-resistant heart failure affects millions globally and is associated with persistently elevated pressures, recurrent hospitalizations, and poor long-term outcomes. Temporary caval flow (preload) modulating catheters have shown clinical and hemodynamic benefits in patients hospitalized with congestion by lowering renal vein pressures and enhancing diuresis. However - while promising - these temporary catheters only provide temporary relief.

Working with leading clinicians, Relief Cardiovascular has developed the Relief System, the world’s first transcatheter preload modulating implant. Unlike existing transcatheter implants, the Relief System enables autonomous hemodynamic monitoring paired with the ability to modulate venous return, providing a new means of improving perfusion and decongestion for the millions of heart failure patients whose needs are inadequately met today.

The development of transcatheter heart failure therapies has lagged behind the progress in other cardiovascular domains, with heart failure treatment remaining dominated by pharmaceuticals and legacy devices. Relief Cardiovascular represents a new direction: targeting hemodynamics directly with a transcatheter implant that can be personalized, monitored, and adjusted over time. Early preclinical data, including multiple chronic large animal studies, demonstrate sustained control of venous pressures, favorable histopathology, and long-term implant safety.

Headquartered in Orange County, California, Relief Cardiovascular has assembled a dedicated team with decades of experience and expertise in the development, manufacture, and commercialization of heart valves, active implants, and catheter-based technologies. The company is backed by influential cardiovascular-focused investors, including Broadview Ventures, Advent Life Sciences, Good Growth Capital, and Heartwork Capital.

Caution:  The Relief System is not available in the USA for clinical trials or for commercialization